Sponsor & Developer Portfolio

Takeda

Clinical development pipeline, platform architecture, and registered trial tracking for Takeda vaccine candidates.

4
Candidates
3
Target Diseases
5
Linked Studies

Development Phase Distribution

Phase 3 Clinical Trial: 2 Discontinued / Inactive: 2

Platform Technologies

Biological (unspecified platform): 3 Inactivated: 1

Target Pathogens & Indications

Dengue Polio Zika

Vaccine Pipeline Candidates (4)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Discontinued / Inactive ctgov-purified-inactivated-zika-virus-vaccine-pizv-takeda

PIZV (TAK-426, purified inactivated Zika virus vaccine)

Target: Zika

Platform: Inactivated

Key Milestone: Primary completion (most advanced trial): 2024-07-05 (registry estimate)
Discontinued / Inactive ctgov-sabin-based-inactivated-poliomyelitis-vaccine-sipv-takeda

TAK-195 (Sabin-based inactivated poliovirus vaccine, sIPV)

Target: Polio

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2018-04-03 (registry estimate)
Phase 3 Clinical Trial ctgov-tdv-takeda

TDV

Target: Dengue

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2030-03-03 (registry estimate)
Phase 3 Clinical Trial ctgov-tetravalent-dengue-vaccine-tdv-takeda

Tetravalent Dengue Vaccine (TDV)

Target: Dengue

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2026-06-29 (registry estimate)

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →